Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
VTRS
VTRS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VTRS News
SPYD ETF 52-Week Price Analysis
3d ago
NASDAQ.COM
US Stocks Rise on Monday as Tech Stocks Rebound
5d ago
NASDAQ.COM
UBS Upgrades Viatris to Buy, Raises Price Target to $11
6d ago
seekingalpha
Major Wall Street Rating Updates on Monday
6d ago
CNBC
Viatris Announces Q4 and Full Year 2025 Financial Results Release
Feb 03 2026
PRnewswire
Viatris Announces Q4 and Full Year 2025 Financial Results Release
Feb 03 2026
Newsfilter
Mapi Pharma Presents New GA Depot Data at ACTRIMS Forum 2026
Feb 03 2026
Newsfilter
Viatris Appoints New Chief Legal Officer Following Brian Roman's Departure
Feb 03 2026
PRnewswire
Viatris (VTRS) Launches Inpefa in UAE, Plans Future Expansions Across Multiple Countries
Jan 20 2026
NASDAQ.COM
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
Jan 08 2026
PRnewswire
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
Jan 08 2026
Newsfilter
Viatris Secures FDA Approvals for Four New Drugs, Advancing R&D Progress
Dec 18 2025
PRnewswire
FDA Greenlights Viatris' Generic Version of Sandostatin LAR Depot; Weekly Contraceptive Patch Under Review Next July
Dec 18 2025
NASDAQ.COM
Viatris to Present at J.P. Morgan Healthcare Conference on January 13, 2026
Dec 17 2025
PRnewswire
Is Viatris' Restructuring Strategy Justified Following Recent Fluctuations in Share Price?
Dec 16 2025
Yahoo Finance
Vera Therapeutics Prices Public Offering at $42.50, Raising Approximately $261 Million
Dec 10 2025
Globenewswire
Show More News
